ROG

Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment

Retrieved on: 
Friday, December 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ROG, Risk, Disease, Trastuzumab emtansine, Rated R, Recurrence, OS, Roche, EBC, Death, Pharmaceutical industry, Trastuzumab, Genentech

Data also show that the previously reported invasive disease-free survival (primary endpoint) benefit is maintained.

Key Points: 
  • Data also show that the previously reported invasive disease-free survival (primary endpoint) benefit is maintained.
  • “With these new data, Kadcyla is the first targeted therapy to demonstrate a significant survival benefit in people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment."
  • Approximately one in five people with breast cancer will be HER2-positive, a particularly aggressive form of the disease.
  • Kadcyla is also approved for the treatment of people with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane.

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Retrieved on: 
Tuesday, December 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Progression-free survival, Fulvestrant, PIK3CA, Breast cancer, Patient, Roche, PFS, ROG, Survival, Phase, HIV disease progression rates, Genentech

Overall survival data were immature at this time, but a clear positive trend has been observed.

Key Points: 
  • Overall survival data were immature at this time, but a clear positive trend has been observed.
  • “These pivotal study results for this inavolisib combination represent a transformative medical advance for people with PIK3CA-mutated HR-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.
  • With this unique dual mechanism of action, inavolisib may provide well-tolerated, durable disease control and potentially improved outcomes for people with HR-positive/HER2-negative, PIK3CA-mutated advanced breast cancer.
  • Inavolisib is currently being investigated in three Phase III clinical studies in people with PIK3CA-mutated metastatic breast cancer (INAVO120, INAVO121, INAVO122) in various combinations.

Rogers to Participate in UBS Global Technology Conference

Retrieved on: 
Tuesday, November 21, 2023
Hardware, Chemicals, Plastics, Semiconductor, Automotive Manufacturing, Alternative Energy, Energy, Manufacturing, Technology, EV, Electric Vehicles, Other Technology, Other Manufacturing, Machinery, Automotive, Mobile, Wireless, Engineering, EST, ROG, MST, NYSE, Conference, Senior, Rogers Corporation, Management, Life insurance

Rogers Corporation (NYSE:ROG) announced today that Colin Gouveia, President and Chief Executive Officer, and Ram Mayampurath, Senior Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Technology Conference on Tuesday, November 28, 2023 at 3:35 pm MST (5:35 pm EST).

Key Points: 
  • Rogers Corporation (NYSE:ROG) announced today that Colin Gouveia, President and Chief Executive Officer, and Ram Mayampurath, Senior Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Technology Conference on Tuesday, November 28, 2023 at 3:35 pm MST (5:35 pm EST).
  • A live webcast of the event, and subsequent replay, will be available on Rogers’ investor relations website at https://rogerscorp.com/investors .

Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development

Retrieved on: 
Tuesday, November 21, 2023
Health, Technology, Health Technology, Software, Artificial Intelligence, Pharmaceutical, Biotechnology, Cloud, Development, Research, Disease, Roche, Algorithm, Science, ROG, EVP, NVIDIA, Therapy, Drug discovery, AI, Biology, Drug development, Medical device, Video game, Pharmaceutical industry, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.
  • The collaboration is designed to significantly enhance Genentech’s advanced AI research programs by transforming its generative AI models and algorithms into a next-generation AI platform, expediting the discovery and delivery of novel therapies and medicines to people.
  • The companies will join forces to accelerate and optimize Genentech’s proprietary machine learning (ML) algorithms and models on NVIDIA DGX Cloud , which provides a training-as-a-service platform built on dedicated NVIDIA AI supercomputing and software, including NVIDIA BioNemo for generative AI applications in drug discovery.
  • “Our collaboration to create Genentech’s next-generation AI platform will dramatically accelerate the pace of drug discovery and development.”
    The collaboration with NVIDIA complements Genentech’s AI/ML teams, which are developing and leveraging AI and ML foundational models across numerous research areas including diverse therapeutic modalities.

Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges

Retrieved on: 
Monday, November 20, 2023
Research, Gold, Patient, PCR, FDA, Laboratory, ROG, Infection, Tron Lightcycle Power Run, Diagnosis, Cancer, Health care, Hospital, Real-time, Medical imaging, Fine chemical, Roche

The LightCycler PRO System is designed to be the most advanced qPCR technology for both clinical diagnostics and research.

Key Points: 
  • The LightCycler PRO System is designed to be the most advanced qPCR technology for both clinical diagnostics and research.
  • The new system will advance personalised healthcare and support outbreak readiness by delivering agility and flexibility for translational research and diagnostics.
  • Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics.
  • "Roche has made significant contributions in establishing and advancing PCR technology to address the needs of healthcare systems," said Josh Lauer, Head of Molecular Labs at Roche Diagnostics.

Black Friday ASUS Deals 2023: Best Early ROG, TUF, Vivobook, Zenbook & More ASUS Laptop, Monitor & Desktop PC Savings At Walmart Summarized by Consumer Walk

Retrieved on: 
Thursday, November 2, 2023
Technology, Hardware, Consumer Electronics, Republic, Electronics, Black Friday, Falls, TUF, ASUS, ROG, Walmart, ZenBook, Video game

Consumer Walk earns commissions from purchases made using the links provided.

Key Points: 
  • Consumer Walk earns commissions from purchases made using the links provided.
  • ASUS, a prominent name in the tech industry, offers an extensive range of consumer electronics and computer hardware.
  • This year's date falls on November 24, igniting the holiday shopping season with incredible deals and discounts across various product categories.
  • Shoppers can expect significant price reductions on a wide range of electronics, from laptops and gaming devices to peripherals and accessories.

JSAUX RELEASES A ROG ALLY MODCASE AND A TRANSPARENT RGB BACKPLATE

Retrieved on: 
Friday, October 27, 2023
Sale, Electronics, ROG, Video game, Cryptocurrency

HONG KONG, Oct. 27, 2023 /PRNewswire/ -- Electronics manufacturer JSAUX has just announced the release of two new products for the ROG Ally: the PC0109 ROG Ally Modcase as well as the PC0110 ROG Ally Transparent RGB Backplate. The ModCase comes in two versions- a basic kit with the case and two tape straps to attach accessories to the device and a power bank kit that also includes a 20,000mAh power bank (65W) to extend gaming sessions. Both items are already available at the official JSAUX website. The company is also hosting a Halloween sale that will run from today until November 1. Gamers can check it in this link.

Key Points: 
  • HONG KONG, Oct. 27, 2023 /PRNewswire/ -- Electronics manufacturer JSAUX has just announced the release of two new products for the ROG Ally: the PC0109 ROG Ally Modcase as well as the PC0110 ROG Ally Transparent RGB Backplate .
  • The ModCase comes in two versions- a basic kit with the case and two tape straps to attach accessories to the device and a power bank kit that also includes a 20,000mAh power bank (65W) to extend gaming sessions.
  • Both items are already available at the official JSAUX website.
  • The company is also hosting a Halloween sale that will run from today until November 1.

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

Retrieved on: 
Friday, October 27, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, ROG, Food, Ranibizumab, RO, AMD, DME, Injection, Warning, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Retinal vasculitis, RVO, Diabetic retinopathy, Colic flexures, Paratriathlon, Vascular occlusion, Roche, Eye, Macular edema, Neovascularization, Pharmaceutical industry, Vaccine, Faricimab, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).
  • RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
  • Together, the three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss.
  • This was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluid.

Roche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses

Retrieved on: 
Thursday, October 26, 2023
Digital, Laboratory, Research, Incidence, ROG, IVD, Marie Cassidy, RO, Pathology, Amazon Web Services, Health, Artificial intelligence, Ibex, Collaboration, Ecosystem, Hospital, Digital pathology, AWS, Algorithm, Cancer, AI, Breast, Diagnosis, Medical imaging

Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.

Key Points: 
  • Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.
  • Digital pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis.
  • Digital pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and providing an opportunity for collaboration in pathology workflows.
  • "This exciting collaboration brings powerful AI solutions to pathology labs," said Michael Rivers, Lifecycle Leader for Roche Digital Pathology.

Roche collaborates with Ibex and Amazon Web Services to accelerate adoption of AI-enabled digital pathology solutions to help improve cancer diagnoses

Retrieved on: 
Thursday, October 26, 2023
Digital, Laboratory, Research, Incidence, ROG, IVD, Marie Cassidy, RO, Pathology, Amazon Web Services, Health, Artificial intelligence, Ibex, Collaboration, Ecosystem, Hospital, Digital pathology, AWS, Algorithm, Cancer, AI, Breast, Diagnosis, Medical imaging

Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.

Key Points: 
  • Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.
  • Digital pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis.
  • Digital pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and providing an opportunity for collaboration in pathology workflows.
  • "This exciting collaboration brings powerful AI solutions to pathology labs," said Michael Rivers, Lifecycle Leader for Roche Digital Pathology.